Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Citations
1,403 citations
Cites background from "Tisagenlecleucel in Adult Relapsed ..."
...Two CD19 CAR T cell products were recently approved in the United States and Europe [1-4], andmore indications are expected in the coming years....
[...]
...In this new field of medicine, companies may have to face the possibility of a gap between what the FDA or European Medicines Agency (EMA) wants them to collect and what centers are actually able to provide....
[...]
...Two CAR T products were recently approved in the United States and Europe for the treatment of patients up to age 25 years with relapsed or refractory B cell acute lymphoblastic leukemia and/or adults with large B cell lymphoma....
[...]
1,025 citations
950 citations
875 citations
612 citations
References
4,797 citations
3,363 citations
3,326 citations
3,237 citations
1,497 citations